RA
XERS icon

Rosalind Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Rosalind Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23M Sell
2,908,981
-322,719
-10% -$2.06M 8.56% 3
2026
Q1 		$18.7M Buy
3,231,700
+1,120,000
+53% +$7.43M 7.53% 2
2025
Q4 		$16.6M Buy
2,111,700
+315,934
+18% +$2.49M 5.83% 4
2025
Q3 		$14.6M Sell
1,795,766
-359,828
-17% -$2.39M 5% 6
2025
Q2 		$10.1M Sell
2,155,594
-340,392
-14% -$1.56M 4.77% 6
2025
Q1 		$13.7M Sell
2,495,986
-609,009
-20% -$2.46M 6.66% 3
2024
Q4 		$10.5M Hold
3,104,995
– – 5.38% 5
2024
Q3 		$8.85M Sell
3,104,995
-15,175
-0.5% -$39K 5.67% 7
2024
Q2 		$7.02M Buy
3,120,170
+300,000
+11% +$605K 5.4% 6
2024
Q1 		$6.23M Sell
2,820,170
-723,515
-20% -$1.87M 5.82% 5
2023
Q4 		$8.33M Buy
+3,543,685
New +$6.54M 6.86% 4

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rosalind Advisors's XERS Position: Q2 2026 in Review

Rosalind Advisors reduced its Xeris Biopharma Holdings (XERS) stake by 10% in Q2 2026, selling an estimated $2.06M and leaving 2,908,981 shares worth $23M. The position accounts for 8.56% of the portfolio, ranked #3.

Rosalind Advisors first reported a position in XERS in Q4 2023 and has held it in 11 quarters since. 239 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Rosalind Advisors held 2,908,981 shares of Xeris Biopharma Holdings worth $23M as of Q2 2026.
  • Rosalind Advisors sold 322,719 Xeris Biopharma Holdings shares in Q2 2026, an estimated $2.06M.
  • Xeris Biopharma Holdings made up 8.56% of Rosalind Advisors's portfolio in Q2 2026, its #3 holding.
  • Rosalind Advisors first reported a position in Xeris Biopharma Holdings in Q4 2023 and has held it in 11 quarters since.
  • 239 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Rosalind Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.